India, Oct. 8 -- Clearmind Medicine (CMND) announced the publication in Japan of a patent application covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements.
The published application covers the use of 3-Methylmethcathinone (3-MMC) for preventing, treating or reducing dyskinesia symptoms, including pharmaceutical compositions containing 3-MMC.
The patent application also includes claims covering combinations of 3-MMC with N-acylethanolamines, including Palmitoylethanolamide (PEA), a compound with established anti-inflammatory and neuroprotective properties.
The patent applications are part of an ongoing collaboration between Clearmind and NeuroThera Labs (N...